Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab versus oral migraine prophylactics in episodic migraine after 1-2 prior preventive failures
NL-OMON55516Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of erenumab in migraine (2 arms), sponsored by Novartis. Primary endpoint: Sustained benefit at month 12. Started Jul 2019; status: active, not recruiting.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON55516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55516.